ArticleJournal of the Endocrine Society2026
Insulin receptor expression and its association with hyperinsulinemia in triple negative breast cancer.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Obesity-related Metabolic Dysfunction and Triple-negative Breast Cancer: Epidemiologic Signals, Mechanistic Pathways, and Opportunities for Prevention.Current obesity reports · 2026Review
- DeepIR-Pred: identification of insulin receptors using metaheuristic optimization of biologically informed multi-view features with deep recurrent learning.Briefings in bioinformatics · 2026Article
- Insulin receptor expression and its association with hyperinsulinemia in triple negative breast cancer.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Purpose: Hyperinsulinemia and tumor insulin receptor (IR) expression have been associated with triple negative breast cancer (TNBC) progression in preclinical models. We aimed to evaluate the expression of the IR, IGF-1 receptor (IGF-1R), and associated signaling protein expression in TNBC and their correlations with demographic and metabolic parameters in a population of women with TNBC. Methods: We identified cases of TNBC from our multi-institutional, cross-sectional study of self-identified Black and White women with newly diagnosed breast cancer. Survey, anthropometric, screening behavior, laboratory, and tumor pathology reports were collected, along with formalin-fixed paraffin embedded tumor samples. We performed immunohistochemistry (IHC) analysis and quantified the expression of IR, IGF-1R, phosphorylated Erk1/2 (pErk1/2), and FOXO3a. Clinical information was correlated with IHC scoring. Results: There were 93 TNBC cases. IHC staining and quantification found that 63% of TNBC cases stained positive for IR, 73% for IGF-1R, 67% for FOXO3a, and 43% for pErk1/2. Positive IR staining was more prevalent in Black women than White women ( Conclusion: Tumor IR expression was associated with higher fasting insulin, and higher fasting insulin was more prevalent among Black women. Further studies are needed to determine the importance of hyperinsulinemia and tumor IR expression in the development of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.